HRTS logoHRTS
GLP-1, Obesity & Cardiometabolic ETF

75
Loading...
Loading...
News
all
press releases
News Placeholder
Ascendis Pharma Eyes Best Open In A Month After Q4 Print, But BofA Cuts Price Target: Retail Gets Buzzing
The brokerage adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp.
Stocktwits·7mo ago
News Placeholder
Keros Therapeutics Stock Heads For Record Low After Dosing Halt In Pulmonary Disease Trial, Retail Buzz Spikes
The company’s stock declined nearly 60% in 2024 and has lost an additional 21% in 2025, with this latest setback further dampening investor confidence.
Stocktwits·8mo ago

Latest HRTS News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.